1887

n CME : Your SA Journal of CPD - Management of dyslipidaemia : main topic

USD

 

Abstract

Dyslipidaemia, particularly an elevated LDL-cholesterol level, is the major risk factor for cardiovascular disease. <br>Lifestyle modification is essential and must be applied to all patients with dyslipidaemia. <br>Patients with genetic dyslipidaemia, established cardiovascular disease, diabetes, and those at high cardiovascular risk warrant lipid-modifying drug therapy. <br>Appropriately prescribed lipid-modifying drug therapy can lower cardiovascular morbidity and mortality and improve overall survival. <br>Statins are the most effective agents for the treatment of predominant hypercholesterolaemia. <br>Fibrates are more effective for the treatment of hypertriglyceridaemia. <br>Combination therapy may be required for the treatment of severe dyslipidaemia but side-effects are more likely and costs become substantial.

Loading

Article metrics loading...

/content/m_cme/21/7/EJC62605
2003-07-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error